DS-1971

DS-1971 (also known as DS-1971a) is a potent and selective small molecule inhibitor of the voltage-gated sodium channel NaV1.7 (Sodium channel protein type IX alpha subunit). It was developed by Daiichi Sankyo for the oral treatment of chronic pain conditions such as neuropathic pain and radiculopathy. Preclinical studies demonstrated high selectivity and efficacy in models of peripheral neuropathic pain with a favorable safety profile. Clinical development reached up to phase 2 trials for indications including diabetic peripheral neuropathic pain, neuralgia, radiculopathy, and spinal stenosis before being discontinued[2][3][5][8].

Other names

1450595-86-4EHV5F71MBFEHV-5F71MBFEHV 5F71MBF5-chloro-2-fluoro-4-[(1S,2R)-2-(2-methylpyrazol-3-yl)cyclohexyl]oxy-N-pyrimidin-4-ylbenzenesulfonamide